Status:
COMPLETED
Study to Assess Safety & Tolerability of AZD2281 in Combination With Bevacizumab in Patients With Advanced Solid Tumours
Lead Sponsor:
AstraZeneca
Conditions:
Neoplasm Metastasis
Eligibility:
All Genders
18+ years
Phase:
PHASE1
Brief Summary
Phase I, open label, dual centre, dose finding study to evaluate the safety and tolerability of continuous twice daily oral dosing with AZD2281 when administered in combination with Bevacizumab 10mg/k...
Eligibility Criteria
Inclusion
- Histologically confirmed metastatic cancer, not amenable to surgery or radiation therapy with curative intent
- Adequate bone marrow, kidney and liver function in accordance with laboratory parameters set out in the protocol
- Estimated life expectancy of at least 12 weeks
Exclusion
- Disorders that may put the patient at risk of bleeding, including gastrointestinal perforation, intra-abdominal abcess, major surgery of the chest or abdomen, previous haemorrhage, coughing up blood or thrombotic event
- Hypertension (high blood pressure) or significant cardiovascular disease
- Hypersensitivity to Chinese hamster ovary cell products or other recombinant or humanised antibodies
Key Trial Info
Start Date :
June 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 1 2009
Estimated Enrollment :
18 Patients enrolled
Trial Details
Trial ID
NCT00710268
Start Date
June 1 2008
End Date
November 1 2009
Last Update
January 14 2015
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Manchester, United Kingdom
2
Research Site
Oxford, United Kingdom